Company / EPS (Diluted)
Travere Therapeutics, Inc. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$1.50
FY2025
5-year range
-$4.37 / -$1.50
FY2021-FY2025
Trend
+65.7%
vs FY2024
Sector context
#108 of 204
Health Care
What the data says
At $-1.50, Travere Therapeutics, Inc.'s eps (diluted) ranks #108 of 204 in the Health Care sector. EPS (Diluted) has fluctuated over the past 10 years, ranging from $-4.43 in FY2016 to $3.17 in FY2017.
Based on SEC 10-K filings.
-1.50 in FY2025.
Improved from $-3.01 to $-1.50 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#108 of 204 in Health CareTop 53% of 204This company -$1.50 Sector average -$0.89
▼
-69.3% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 65.7% year-over-year.
- Ranks #108 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2017.
- Lowest eps (diluted) in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.50 | +65.7% |
| FY2024 | -$4.37 | -45.2% |
| FY2023 | -$3.01 | +15.4% |
| FY2022 | -$3.56 | -2.9% |
| FY2021 | -$3.46 | -36.2% |
| FY2020 | -$2.54 | -64.9% |
| FY2019 | -$1.54 | -19.4% |
| FY2018 | -$1.29 | -140.7% |
| FY2017 | $3.17 | +171.6% |
| FY2016 | -$4.43 | -81.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026